Loading...
XETRPSG
Market cap299mUSD
Dec 23, Last price  
24.00EUR
1D
1.69%
1Q
13.21%
IPO
-28.99%
Name

PharmaSGP Holding SE

Chart & Performance

D1W1MN
XETR:PSG chart
P/E
17.55
P/S
2.85
EPS
1.37
Div Yield, %
2.04%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
10.78%
Revenues
101m
+17.80%
53,062,00060,595,00062,574,00063,246,00065,344,00085,824,000101,099,000
Net income
16m
+37.17%
11,783,00014,733,00016,706,00010,640,00010,690,00011,954,00016,397,000
CFO
27m
+7.79%
14,237,0008,422,00017,631,00015,458,00012,240,00024,713,00026,639,000
Dividend
Jun 27, 20241.36 EUR/sh
Earnings
Jun 26, 2025

Profile

PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.
URL
https://pharmasgp.com/
IPO date
Jun 19, 2020
Employees
79
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
101,099
17.80%
85,824
31.34%
65,344
3.32%
Cost of revenue
60,185
46,410
38,273
Unusual Expense (Income)
NOPBT
40,914
39,414
27,071
NOPBT Margin
40.47%
45.92%
41.43%
Operating Taxes
5,496
3,849
3,516
Tax Rate
13.43%
9.77%
12.99%
NOPAT
35,418
35,565
23,555
Net income
16,397
37.17%
11,954
11.82%
10,690
0.47%
Dividends
(5,875)
(5,400)
Dividend yield
Proceeds from repurchase of equity
(286)
BB yield
Debt
Debt current
8,155
8,063
85,193
Long-term debt
66,718
2,036
195
Deferred revenue
Other long-term liabilities
339
73,225
62
Net debt
32,857
(24,627)
64,564
Cash flow
Cash from operating activities
26,639
24,713
12,240
CAPEX
(53)
(787)
(83,459)
Cash from investing activities
(866)
(787)
(83,459)
Cash from financing activities
(17,649)
(12,108)
84,042
FCF
31,735
35,756
21,164
Balance
Cash
40,766
33,882
20,824
Long term investments
1,250
844
Excess cash
36,961
30,435
17,557
Stockholders' equity
1,634
(7,023)
22,197
Invested Capital
112,436
119,859
89,270
ROIC
30.49%
34.01%
49.06%
ROCE
35.62%
34.55%
25.28%
EV
Common stock shares outstanding
11,993
12,000
12,000
Price
Market cap
EV
EBITDA
50,210
48,664
30,644
EV/EBITDA
Interest
4,410
2,007
643
Interest/NOPBT
10.78%
5.09%
2.38%